Tripep Interim report January -- June 2003

HUDDINGE, Sweden, Sept. 01, 2003 (PRIMEZONE) -- Tripep AB (publ):

- Result after tax: -SEK 11.9 million (-SEK 32.5 m). Research and development costs: SEK 6.6 million (SEK 9.4 m). The company has no other income. EPS: -SEK 0.86 (-SEK 2.34).

Research into Tripep's new anti-HIV medication, MetaboliteX, continues.

The share buyback offer was 97.9% subscribed, entailing a transfer of around SEK 40.7 million to the shareholders.

Evaluation of the patent situation in Isconova AB was deemed to be excessively complicated and Tripep's Board of Directors has consequently decided not to implement the planned acquisition.

It was decided, after the period end, that Tripep, in partnership with researchers at the Vaccine Research Institute of San Diego (VRISD), would form a new vaccine development company in the USA. The company will be known as VLP Biotech Inc.

The National Swedish Tax Board has issued general advice guidelines with regard to the buyback of shares in Tripep.

For additional information, please contact Johan Ihre, CEO Tel: +46 8 449 84 80, mobile: +46 707 33 44 25 e-mail: johan.ihre@tripep.se or Anders Vahlne, Vice President, Head of Research Tel: +46 8 58581 313, mobile: +46 709 28 05 28 e-mail: anders.vahlne@labmed.ki.se

Tripep is a biotech research company that develops and commercialises candidate drugs based on patented technologies:

-- research and development of a potential HIV-inhibiting drug,

-- preclinical research focusing on the development of therapeutic and prophylactic vaccines for HIV and hepatitis C, and

-- the RAS(R) technology platform.

For a description of the company's technologies, please see the company's homepage at www.tripep.se

Tripep Interim report January -- June 2003

Tags

Kontaktdaten

Kontakt